JPY 1514.0
(-0.26%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Cash Flow | 2.37 Billion | 430.86 Million | 1.38 Billion | 1.05 Billion | -463.03 Million |
Net Income | 1.07 Billion | 769.8 Million | 1.64 Billion | 611.29 Million | -129.72 Million |
Depreciation & Amortization | 465.36 Million | 382.5 Million | 283.72 Million | 279.9 Million | 303.46 Million |
Deferred income taxes | - | - | - | - | - |
Stock-based compensation | 8.07 Million | 8.88 Million | 8.47 Million | 14.57 Million | 38.07 Million |
Change in working capital | 135.71 Million | 96.34 Million | -215.43 Million | -530.8 Million | -364.01 Million |
Other non-cash items | 1.82 Billion | -59.01 Million | -62.04 Million | 327.37 Million | -204.73 Million |
Investing Cash Flow | -1.83 Billion | -1.02 Billion | -641.19 Million | -126.97 Million | -599.82 Million |
Investments in PPE | -1.51 Billion | -984.08 Million | -610.98 Million | -135.02 Million | -588.9 Million |
Acquisitions | -306.22 Million | - | - | 10 Thousand | - |
Investment purchases | -427.52 Million | -407.51 Million | -407.51 Million | -407.5 Million | -407.47 Million |
Sales/Maturities of investments | 407.51 Million | 407.51 Million | 407.5 Million | 407.47 Million | 407.43 Million |
Other Investing Activities | 1.08 Million | -39.37 Million | -30.9 Million | 8.77 Million | -10.88 Million |
Financing Cash Flow | -130.55 Million | -14.48 Million | -2.97 Billion | 2.83 Billion | -61.51 Million |
Debt repayment | -6 Million | -72 Million | -2.88 Billion | -2.85 Billion | -36 Million |
Dividends payments | -163.81 Million | -82.2 Million | -82.15 Million | -101 Thousand | -82.14 Million |
Common Stock Repurchased | -134 Thousand | - | - | -93 Thousand | - |
Common Stock Issuance | 27.39 Million | - | - | 314 Thousand | - |
Other Financing Activities | 33 Million | 68 Million | 111 Million | -2000.00 | 21 Million |
Accounts receivables | -134.57 Million | -35 Million | -36 Million | -540 Million | 84 Million |
Accounts payables | -17.15 Million | 39.72 Million | 61.77 Million | -45.66 Million | -609.62 Million |
Inventory | -40.92 Million | -48.36 Million | -42.03 Million | 1.78 Million | 99.62 Million |
Other working capital | 328.36 Million | -55 Million | -61 Million | 343 Million | -171 Million |
Cash at beginning of period | 2.47 Billion | 6.38 Billion | 8.6 Billion | 4.83 Billion | 5.96 Billion |
Cash at end of period | 2.88 Billion | 5.77 Billion | 6.38 Billion | 8.6 Billion | 4.83 Billion |
Capital Expenditure | -1.51 Billion | -984.08 Million | -610.98 Million | -135.02 Million | -588.9 Million |
Effect of forex changes on cash | - | - | - | - | - |
Net cash flow / Change in cash | 405.05 Million | -607.08 Million | -2.22 Billion | 3.76 Billion | -1.12 Billion |
Free Cash Flow | 860.81 Million | -553.21 Million | 778.38 Million | 919.8 Million | -1.05 Billion |
Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 177 Million | 1.07 Billion | 279 Million | 222 Million | 205 Million | 367 Million |
Depreciation & Amortization | - | 465.36 Million | - | - | - | - |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | 8.07 Million | - | - | - | - |
Change in working capital | - | 135.71 Million | - | - | - | - |
Other non-cash items | -177 Million | 1.82 Billion | -279 Million | -222 Million | -205 Million | -367 Million |
Investing Cash Flow | - | -1.83 Billion | - | - | - | - |
Investments in PPE | - | -1.51 Billion | - | - | - | - |
Acquisitions | - | -306.22 Million | - | - | - | - |
Investment purchases | - | -427.52 Million | - | - | - | - |
Sales/Maturities of investments | - | 407.51 Million | - | - | - | - |
Other Investing Activities | - | 1.08 Million | - | - | - | - |
Financing Cash Flow | - | -130.55 Million | - | - | - | - |
Debt repayment | - | -6 Million | - | - | - | - |
Dividends payments | - | -163.81 Million | - | - | - | - |
Common Stock Repurchased | - | -134 Thousand | - | - | - | - |
Common Stock Issuance | - | 27.39 Million | - | - | - | - |
Other Financing Activities | - | 33 Million | - | - | - | - |
Accounts receivables | - | -134.57 Million | - | - | - | - |
Accounts payables | - | -17.15 Million | - | - | - | - |
Inventory | - | -40.92 Million | - | - | - | - |
Other working capital | - | 328.36 Million | - | - | - | - |
Cash at beginning of period | - | 2.47 Billion | - | - | - | - |
Cash at end of period | - | 2.88 Billion | - | - | - | - |
Capital Expenditure | - | -1.51 Billion | - | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | 405.05 Million | - | - | - | - |
Free Cash Flow | - | 860.81 Million | - | - | - | - |
9385
8030
8060
4320
PRIMESECU
AUROPHARMA